Evercore ISI Begins Coverage on Kenvue (NYSE:KVUE)

Stock analysts at Evercore ISI began coverage on shares of Kenvue (NYSE:KVUE - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set an "in-line" rating and a $25.00 price target on the stock. Evercore ISI's price objective would indicate a potential upside of 5.33% from the stock's previous close.

Several other research firms have also recently commented on KVUE. Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a report on Friday, January 17th. Citigroup lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Canaccord Genuity Group raised their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $24.00.

Remove Ads

Kenvue Stock Performance

KVUE traded up $0.24 during trading on Monday, hitting $23.74. The stock had a trading volume of 14,401,327 shares, compared to its average volume of 16,745,933. The firm has a market capitalization of $45.36 billion, a P/E ratio of 44.78, a PEG ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The company's 50-day moving average price is $22.32 and its 200 day moving average price is $22.46.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Institutional Trading of Kenvue

A number of hedge funds have recently made changes to their positions in KVUE. Grove Bank & Trust boosted its stake in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. lifted its position in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.